82971-90-2Relevant articles and documents
Synthesis method of indoxacarb intermediate semicarbazone
-
Paragraph 0035; 0036, (2017/08/30)
The invention discloses a synthesis method of an indoxacarb intermediate semicarbazone. The synthesis method includes the steps of producing 4-trifluoromethoxy phenylurea from 4-trifluoromethoxyaniline and isocyanate under the action of acetic acid; enabling the 4-trifluoromethoxy phenylurea and hydrazine hydrate to undergo hydrazinolysis in an organic solvent so as to obtain 4-trifluoromethoxy phenylamino hydrazide; enabling the 4-trifluoromethoxy phenylamino hydrazide and 5-chloro-1,3-dihydro-2-hydroxy-1-oxo-2H-indene-2-carboxylic acid methyl ester in an organic solvent under the action of a catalyst. The synthesis method has the advantages that the intermediate semicarbazone is synthesized from industrially available isocyanate through a series of conversion, and accordingly the synthesis method is free of toxic substances and phosgene products and capable of avoiding the shortcomings of high cost and low yield when precious metals serve as catalysts as well as overcoming the technical defect of low ring-closure reaction yield; the synthesis method is high in safety and is economical and high in yield when used for synthesizing indoxacarb atoms.
Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors
Liao, Weike,Hu, Gang,Guo, Zhuang,Sun, Deyu,Zhang, Lixia,Bu, Yanxin,Li, Yingxiu,Liu, Yajing,Gong, Ping
, p. 4410 - 4422 (2015/08/03)
A series of 4-(2-fluorophenoxy)quinoline derivatives containing an imidazolone moiety were designed, synthesized and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, H460, HT-29 and MKN-45). Most compounds showed moderate to excellent activities in enzyme and cellular assays. The most promising analog, 58 (c-Met IC50 = 1.42 nM), displayed 2.1-, 8.6-fold increase against H460, and MKN-45 cell lines, respectively, compared with foretinib. An analysis of structure-activity relationships revealed that an ortho substituted phenyl ring as well as an N-unsubstituted imidazolone linker is favorable for antitumor activity.
